Physician profile
Hamid Behzadi
NPI 1427105253
$25,323.29
in general payments reported to CMS, 2019-2025
43 companies · $4,421 in 2025
The $4,421 reported for 2025 was more than what 87% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,593 · 2020: $2,225 · 2021: $4,920 · 2022: $2,973 · 2023: $3,749 · 2024: $4,442 · 2025: $4,421.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,532.58 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $4,352.26 | 2019-2025 | Jardiance, Ofev, Stiolto Respimat |
| Astrazeneca Pharmaceuticals LP | $3,553.77 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Abbvie INC. | $3,131.94 | 2021-2025 | Vraylar, Linzess, Viberzi |
| Glaxosmithkline, LLC. | $2,713.70 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Novo Nordisk INC | $1,572.59 | 2020-2025 | Ozempic, Rybelsus |
| Biohaven Pharmaceuticals, INC. | $1,261.46 | 2021 | |
| Lundbeck LLC | $762.12 | 2023-2025 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $759.84 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $750.21 | 2019-2025 | Trintellix |
| Pfizer INC. | $612.49 | 2019-2025 | |
| Amgen INC. | $592.23 | 2020-2025 | Repatha, Otezla, Repatha |
| Astellas Pharma US INC | $581.94 | 2023-2025 | Veozah, Myrbetriq |
| Allergan, INC. | $514.72 | 2019-2020 | |
| Idorsia Pharmaceuticals US INC | $471.54 | 2022-2024 | Quviviq |
| Genzyme Corporation | $466.61 | 2019-2025 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hamid Behzadi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.